Print

Purpose

This research trial studies saliva, semen, and blood samples to determine effects of chemotherapy on fertility in osteosarcoma survivors. Study biospecimen samples from osteosarcoma survivors in the laboratory may help doctors learn whether chemotherapy causes fertility problems and to learn more about the long term effects.

Condition

Eligibility

Eligible Ages
Between 18 Years and 50 Years
Eligible Genders
Male
Accepts Healthy Volunteers
No

Criteria


Inclusion Criteria:

- Received upfront therapies for osteosarcoma, which included cisplatin, (with or
without other agents)

- Patient must have completed cancer treatment >= 2 years prior to study enrollment

- Osteosarcoma survivors without a systemically treated relapse or subsequent malignancy

- Note: History of relapse or second malignancy is permitted if treated with local
therapy only (e.g. surgery, radiation)

- Able to speak, read and write in English, French or Spanish

- All patients and/or their parents or legal guardians must sign a written informed
consent

- All institutional, Food and Drug Administration (FDA), and National Cancer Institute
(NCI) requirements for human studies must be met

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Arm Groups

ArmDescriptionAssigned Intervention
Observational (questionnaire, biospecimen collection) Participants complete a health questionnaire over 30-45 minutes. Patients also provide saliva and semen samples and undergo collection of blood.
  • Procedure: Biospecimen Collection
    Undergo collection of blood and provide saliva and semen samples
    Other names:
    • Biological Sample Collection
    • Biospecimen Collected
    • Specimen Collection
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Other: Questionnaire Administration
    Ancillary studies

More Details

Status
Active, not recruiting
Sponsor
Children's Oncology Group

Study Contact

Detailed Description

PRIMARY OBJECTIVES: I. Determine whether infertility and/or biomarkers of spermatogenesis and steroidogenesis differ in male osteosarcoma survivors treated with cisplatin with or without ifosfamide compared to male controls without a history of cancer. II. Evaluate whether cisplatin with or without ifosfamide for the treatment of osteosarcoma alters sperm deoxyribonucleic acid (DNA) methylation. EXPLORATORY OBJECTIVES: I. Evaluate the role of genetic susceptibility in the development of impairments in spermatogenesis or steroidogenesis with contemporary regimens for the treatment of osteosarcoma. OUTLINE: Participants complete a health questionnaire over 30-45 minutes. Patients also provide saliva and semen samples and undergo collection of blood.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.